Hikma Pharmaceuticals Plc (LON:HIK) shares reached a new 52-week high on Thursday . The company traded as high as GBX 2,089 ($27.30) and last traded at GBX 2,025 ($26.46), with a volume of 1343311 shares changing hands. The stock had previously closed at GBX 1,917.50 ($25.06).
A number of research firms have weighed in on HIK. Peel Hunt reaffirmed an “add” rating on shares of Hikma Pharmaceuticals in a research note on Thursday. Barclays reaffirmed an “equal weight” rating and issued a GBX 1,950 ($25.48) price objective on shares of Hikma Pharmaceuticals in a research note on Friday. Citigroup reaffirmed a “buy” rating and issued a GBX 2,250 ($29.40) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, October 30th. Finally, Numis Securities lowered shares of Hikma Pharmaceuticals to a “hold” rating and set a GBX 1,560 ($20.38) price objective on the stock. in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,459 ($19.06).
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/10/hikma-pharmaceuticals-hik-sets-new-52-week-high-at-2089-00.html.
About Hikma Pharmaceuticals (LON:HIK)
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Story: Find a Trading Strategy That Works
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.